Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor

Kanshaiym, Sakiyeva; Zhurabekova, Gulmira; Abdelazim, Ibrahim A.; Starchenko, Tatyana

doi:10.1016/j.htct.2019.01.008

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Participants were asked during each antenatal care visit about their compliance to iron tablets, and the side effects related to oral iron as metallic taste, gastrointestinal (GIT) intolerance/upset, and/or constipation. The pre-treatment ferritin, hemoglobin, RBCs-MCV, and RBCs-MCH were compared by the post-treatment values in the two studied groups to detect the effcacy of HIO compared to FF in treatment of IDA during pregnancy as a primary outcome (16)(17)(18)(19).…”

Section: Methodsmentioning

confidence: 99%

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Abdelazim

Abu-Faza

Al-Ajmi

et al. 2021

Gynecol Obstet Reprod Med

Self Cite

View full text Add to dashboard Cite

OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.

show abstract

Section: Methodsmentioning

confidence: 99%

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Abdelazim

Abu-Faza

Al-Ajmi

et al. 2021

Gynecol Obstet Reprod Med

Self Cite

View full text Add to dashboard Cite

show abstract

Heme-Iron Optifer Versus Intravenous Iron/Ferosac in Treatment of Iron Efficiency Anemia During Pregnancy

Abdelazim

Shikanova

Karimova

et al. 2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Ferric carboxymaltose for treatment of iron deficiency and iron deficiency anemia caused by abnormal uterine bleeding

Hagras¹,

Hussein²,

Abdelazim³

et al. 2022

View full text Add to dashboard Cite

Introduction Heavy menstrual bleeding leads to depletion of iron stores, with subsequent iron deficiency (ID) and iron deficiency anemia (IDA). To evaluate the efficacy and safety of ferric carboxymaltose (FCM) in treatment of ID/IDA caused by abnormal uterine bleeding (AUB). Material and methods One hundred and twenty women ≥ 40 years old with chronic AUB and ID/IDA were included in this study for correction of ID/IDA. Participants received FCM infusion for correction of ID/IDA. The pre-treatment ferritin, hemoglobin (Hb), red blood cell (RBC) mean corpuscular volume (MCV), and RBC mean corpuscular hemoglobin (MCH) values were compared with the 6- and 12-week post-treatment values. Results The pre-treatment ferritin and Hb levels significantly increased from 13.2 ±7.4 µg/l and 8.8 ±0.8 g/dl, respectively, to 111.5 ±5.6 µg/l and 13.9 ±0.6 g/dl, respectively, 6 weeks after FCM ( p = 0.001 and 0.0009; respectively), and to 98.7 ±6.1 µg/l and 12.9 ±0.65 g/dl, respectively, 12 weeks after FCM ( p = 0.01 and 0.01; respectively). In addition, the pre-treatment RBC MCV and RBC MCH values significantly increased from 74.3 ±2.3 fl and 26.6 ±5.3 pg, respectively, to 88.7 ±1.9 fl and 29.6 ±4.5 pg, respectively, 6 weeks after FCM ( p = 0.01 and 0.03, respectively), and to 93.3 ±1.75 fl and 30.3 ±3.8 pg, respectively, 12 weeks after FCM ( p = 0.001 and 0.0001, respectively). Conclusions FCM was safe and effective for correction of ID/IDA caused by chronic AUB within 6 weeks. The serum ferritin, Hb, and RBC indices remained significantly high compared to the pre-treatment values 12 weeks after FCM infusion.

show abstract

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor

Cited by 3 publications

References 8 publications

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Heme-Iron Optifer Versus Intravenous Iron/Ferosac in Treatment of Iron Efficiency Anemia During Pregnancy

Ferric carboxymaltose for treatment of iron deficiency and iron deficiency anemia caused by abnormal uterine bleeding

Contact Info

Product

Resources

About